TEHRAN (FNA) - A faculty member of Tehran University of Medical Sciences announced that the results of studies show effectiveness of Iran’s COVIran Barekat vaccine against the Delta variant of the coronavirus.
“The effectiveness of Barekat vaccine on Delta coronavirus was evaluated in a neutralization test (CVNT),” Mohammad Reza Salehi, also supervisor of the clinical trial of the COVIran Barekat vaccine said.
A neutralization test detects neutralizing antibodies (NAbs) in a patient’s blood.
Salehi added that it was found that people who received COVIran Barekat vaccine in phases one and two, have an effective antibody against Delta coronavirus.
“The first Iranian coronavirus vaccine had already defeated the UK and South African variants of the coronavirus, and we are preparing an article on it to publish the scientific results,” he pointed out.
In relevant remarks earlier in July, Head of the public relations office of Iran’s Headquarters for Executing the Order of Imam (HEIKO) Hojjatollah Nikmaleki announced that over 2mln doses of the indigenous coronavirus vaccine, COV-Iran Barekat, had been produced and would be provided to the health ministry.
“So far, 2,50,000 doses of Barekat coronavirus vaccine have been produced. Since earlier this week, the production capacity has been increased and now we have 1.2mln doses of vaccine production per week,” Nikmaleki said.
“We will meet our promise to produce more than 50mln doses of vaccine by the end of September with the increase of capacities,” he added.
NikMaleki said that each vaccine has a two-week quality control process after production and 400,000 doses have so far passed the process, adding that the health ministry is responsible for injecting the vaccine.